According to Towards Healthcare, the global
viral
vector development market size is valued at USD 0.89 billion in 2024
and is expected to grow to USD 1.06 billion in 2025, projected to reach
approximately USD 5 billion by 2034, expanding at a robust CAGR of 18.84% from
2025 to 2034.

The Complete Study is Now Available for
Immediate Access | Download the Sample Pages of this Report@ https://www.towardshealthcare.com/download-sample/5783

Growth factors in the global viral vector
development market are the rising
number of gene and cell therapy products in development, with major
investments by many governments and private firms in the healthcare system and
R&D sector. As well as numerous breakthroughs in vector design and
manufacturing, like cell lines, purification methods, and expansion
of clinical trials, are driving the overall market growth.

The Viral Vector Development Market:
Highlights

•
 The viral vector development
market will likely exceed USD 0.89 billion by 2024.

•
 Valuation is projected to hit USD
5 billion by 2034.

•
 Estimated to grow at a CAGR of
18.84% from 2025 to 2034.

•
 North America was dominant in the
market in 2024.

•
 Asia Pacific is expected to be
the fastest-growing region during 2025-2034.

•
 By virus, the adeno-associated
viral vectors segment dominated the market in 2024.

•
 By virus, the retrovirus segment
is expected to grow at a notable CAGR in the upcoming years.

•
 By expression system, the transient
segment led the market in 2024.

•
 By expression system, the stable
segment is expected to register rapid expansion during the forecast period.

•
 By application, the gene therapy
segment dominated the global viral vector development market in 2024.

•
 By application, the cancer
therapy segment is expected to grow rapidly in the studied years.

•
 By end user, the pharmaceutical
& biotechnology companies segment held a major revenue share of the market
in 2024.

•
 By end user, the contract
research organization (CRO) segment is expected to show the fastest growth
during 2025-2034.

Market Overview: Cell and Gene Therapy
Pipeline

Necessarily altered viruses that are
employed in delivering genetic material into cells, especially for gene
therapy or vaccine development, can be done by using a viral vector.
The viral vector development market is fueled by advances in production
technologies, expansion in the gene and cell
therapy pipeline, and enhanced investments in healthcare systems.
Nowadays, accelerated focus on vector engineering, delivery methods, and a
higher understanding of safety profiles, resulting in escalated promise in
their use, even in vulnerable populations like infants and the elderly. 

Key Metrics and Overview

Metric

Details

Market Size in 2025

USD 1.06 Billion

Projected Market Size in 2034

USD 5 Billion

CAGR (2025 – 2034)

18.84%

Leading Region

North America

Market Segmentation

By Virus, By Expression System, By Application, By End User, By
Region

Top Key Players

Lonza Group AG, Merck KGaA, Thermo Fisher Scientific Inc.,
Catalent Inc., WuXi AppTec, FUJIFILM Corporation, Oxford Biomedica.

You can place an order or ask any
questions, please feel free to contact us at sales@towardshealthcare.com

Progress in Gene Therapy and Vaccinology
Area: Major Potential

Many kinds of applications are comprised in
the market, mainly gene therapy and vaccinology, which are being highly
influenced. In the viral vector development market, gene therapy encompasses
the utilization of viral vectors to replace damaged genes. Also, this developed
gene therapy is incorporated into in vivo or cells, which can be changed by ex
vivo approaches. Whereas, in the case of vaccinology, viral vectors are widely
employed in vaccine development by inserting emerging genetic material from a
pathogen into a harmless viral vector, triggering an immune response. 

Production Difficulties and Scalability:
Major Limitation

The arising production complexities due to
a shortage of specialized knowledge and high expenditure for infrastructure are
creating a major hurdle for the market. Moreover, scaling up from small-scale
to commercial-scale manufacturing raises concerns regarding vector yield,
stability, and purity.

The Viral Vector Development Market:
Regional Analysis

In 2024, North America held the largest
share of the market. Due to its strong
biotechnology infrastructure, major research and development
capabilities, and significant funding for gene therapy initiatives are
increasingly impacting the regional market. Besides this, the COVID-19 pandemic
fostered the complete vaccine development, especially in adenoviral vectors are
further fuelling this region’s market growth.

The US is a major region in the viral
vector development market, which has boosted the adoption of innovative
technologies in scalable manufacturing, with optimized vector design. This
supports the production of robust and inexpensive viral vectors across the US.

For instance,

• In February 2025, Cellevate AB, a biotech company developing
next-generation cell culture systems to transform biomanufacturing, launched
Cellevat3d® nanofiber microcarriers at the third Viral Vector Process
Development & Manufacturing Summit.

Around Canada, proactive government
assistance, such as the Strategic Innovation Fund (SIF), is notably expanding
domestic manufacturing capacity and boosting the growth of viral vector
production hubs. As well as increasing collaborations
among pharmaceutical companies, research institutions, and biotech
firms, they are supporting the development and application of viral vectors in
this region.

Become a valued research partner with us
– https://www.towardshealthcare.com/schedule-meeting

The Asia Pacific is Anticipated to Grow
at the Fastest CAGR During the Forecast Period

In the upcoming years, the Asia Pacific
will expand rapidly, due to the growing incidence of chronic diseases and
infectious diseases in the region is fostering the demand for efficient
therapeutic solutions, where viral vectors play a crucial role. As well as
the huge pool of biotechnology companies in this ASAP, are driving the
widespread production of different therapies, including cell and gene therapy,
and vaccine development.

From this ASAP region, the Chinese
government is widely encouraging the biopharmaceutical
industry through many initiatives, such as funding for research and
development, robust regulatory frameworks, and incentives. Besides this,
various biopharmaceutical companies in China are actively investing in cell and
gene therapies, like viral vector development, resulting in greater demand for
manufacturing capabilities in the viral vector development market. 

For instance,

•  In June 2025, Tofersen, an advanced gene-targeted drug for
amyotrophic lateral sclerosis (ALS) patients, was commercially launched by
pharmaceutical giant Biogen in China.

However, India is facing a significant
burden of cancer cases, which ultimately enhances their focus on precision
cancer treatments, particularly CAR-T
cell therapies, which are escalating market growth. Also, India’s
many CMOs are playing a vital role in offering viral vectors on demand, which
is expanding drug development timelines for major healthcare firms. 

The Viral Vector Development Market: Segmentation
Analysis

By virus analysis

The adeno-associated viral vectors segment
held the biggest share of the market in 2024. These types of vectors are safe
due to their non-pathogenic nature and rarely integrate into the host genome.
The segment is driven by rising demand for gene therapies and vaccine research,
alongside advancements in vector design and production. Moreover, AAVs are
widely used in the development
of targeted therapies in different conditions, like cystic fibrosis and
Duchenne muscular dystrophy, neurological disorders, cancers, and eye diseases.

For instance,

•  In July 2025, Myrtelle Inc., a clinical-stage gene therapy company,
introduced commercial-stage manufacturing for oligotrophic recombinant
adeno-associated virus (rAAV) product MYR-101, which has been established to
treat Canavan disease.

The retrovirus segment will expand fastest
in the viral vector development market. Basic utilization of retroviral vectors
in gene therapy to convey therapeutic genes into patient cells, providing
potential treatments for genetic disorders and other diseases. Besides
this, enhanced research funding in biotechnology, mainly in gene therapy and
vaccine development, is driving demand for viral vectors, including retroviral
vectors. 

Latest Drifts in Retrovirus Segment

Company/Organization

Recent Trends

AscellaHealth HUB

(July 2025)

Partnered with Abeona Therapeutics to offer the launch success of
novel cell-based gene therapy and access to treatment for rare disease
patients.

ViroCell Biologics

(July 2025)

Collaborated with AvenCell Therapeutic on retroviral vector
manufacturing to expand the development of novel allogeneic CAR-T therapies
for blood cancers.

Get the latest insights on life science
industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

By expression system analysis

In 2024, the transient segment was dominant
in the global viral vector development market. Because of its broad flexibility
and faster production of proteins, it is attractive for early-stage drug
discovery and development, where flexibility is important. As compared
to other expressions, the transient system is more affordable, mainly in
small-scale or initial phase research activities.

On the other hand, the stable segment is
anticipated to grow fastest during 2025-2034, due to long-term transgene
expression in both dividing and non-dividing cells, especially when used in AAV
vectors, which fuels the segment growth. Also, the minimized immunogenicity of
the vector design is assisting the adoption of a stable expression system.
Continuous research is needed to highlight concerns like immunotoxicity and
off-target effects, which can impact stable expression. 

By application analysis

Primarily, the gene therapy segment led the
global viral vector development market in 2024. Along with the growing genetic
disorder cases, faster innovations in genetic engineering and biotechnology are
boosting the segment growth with the safe use of viral vectors. And, the
integration of CRISPR and AI in production processes is
promoting therapy precision and production efficiency. Moreover, enhanced
awareness of the efficacy of gene-based treatments is propelling adoption among
diverse therapeutic areas. 

Although the cancer therapy segment is
predicted to be the fastest-growing during the forecast period, combined
factors are contributing to the overall segment and market growth, such as a
rise in cancer prevalence, advancements in targeted therapies, and ongoing
R&D activities in the oncology area. As well as different regions
are promoting various cancer programs to boost awareness about novel and
advanced therapies conveniently and affordably. Phenomenal therapies
development is increasingly supporting the market expansion.

By end-user analysis

In the global viral vector development
market, the pharmaceutical & biotechnology companies segment accounted for
a major share in 2024. Enormous innovations in viral vector production, like optimized
cell culture systems and downstream processing techniques, have
accelerated production efficiency and reduced expenses. Furthermore,
regulatory bodies are highly supportive of gene therapies and other advanced
therapies, promoting the development and commercialization of viral
vector-based treatments. 

The contract research organization (CRO) segment
will grow fastest in the projected period. The ongoing number of clinical
trials for both therapeutic and vaccine development necessitates the assistance
of CROs for many stages of research and development. Due to inexpensive
outsourcing and crucial management approaches to handle the associated
difficulties in viral vector development and manufacturing, CROs play a major
role. Additionally, CROs provide specialized expertise in viral vector design,
development, production, and quality control, which can be a barrier for many
companies.

Top Companies and Their Contributions to
the Market

Company

Contributions & Offerings

Lonza Group AG

Lonza offers end-to-end viral vector development and manufacturing
services, including plasmid production, process development, and
cGMP-compliant manufacturing.

Merck KGaA

Through its MilliporeSigma division, Merck provides viral vector
platforms, analytical tools, and custom manufacturing to support gene and
cell therapy development.

Thermo Fisher Scientific Inc.

Offers comprehensive solutions for viral vector production,
including reagents, cell culture systems, purification technologies, and CDMO
services.

Catalent Inc.

Catalent delivers integrated services from plasmid DNA to viral
vector production, with expertise in AAV and lentiviral vectors for gene
therapy applications.

WuXi AppTec

Provides viral vector CDMO services globally, covering vector
design, cell line development, process optimization, and large-scale GMP
manufacturing.

FUJIFILM Corporation

FUJIFILM Diosynth Biotechnologies offers viral vector
manufacturing for gene therapy, leveraging advanced bioprocessing platforms
and scalable production facilities.

Oxford Biomedica

Specializes in lentiviral vector development, offering proprietary
platform technologies, process development, and GMP manufacturing for
advanced therapy products.

Browse Viral Vector and Related Market
Outlooks Through 2034

The global viral vector gene therapy market is
experiencing strong growth momentum, with substantial revenue increases
anticipated from 2025 through 2034.

The non-viral transfection reagents market was valued at USD 1.85 billion in 2024, rising to USD 2.01 billion
in 2025, and is projected to reach USD 4.29 billion by 2034, expanding at a
CAGR of 8.73% during the forecast period.

The viral sensitizers market is also
demonstrating accelerated growth, expanding from USD 2.04 billion in 2024 to
USD 2.34 billion in 2025, and is forecasted to achieve USD 8.02 billion by
2034, with a CAGR of 14.63% between 2025 and 2034.

The viral vaccine cell culture media market reached USD 1.83 billion in 2024, grew to USD 1.94 billion in 2025,
and is projected to hit USD 3.24 billion by 2034, reflecting a CAGR of 5.84%
over the forecast period.

The lentiviral vector market is
expanding rapidly, increasing from USD 360 million in 2024 to USD 426.82
million in 2025, and is expected to reach USD 1.94 billion by 2034, growing at
a CAGR of 18.56%.

The viral vector manufacturing market is
forecasted to grow significantly, from USD 1.5 billion in 2024 to USD 1.82
billion in 2025, and expected to reach USD 10.53 billion by 2034, at a CAGR of
21.64%.

The Asia-Pacific viral vector and plasmid DNA manufacturing market is set to grow from USD 1.38 billion in 2024 to USD 1.68 billion in
2025, and reach approximately USD 10.01 billion by 2034, expanding at a robust
CAGR of 21.93%.

The global viral vector and plasmid DNA manufacturing market, which stood at USD 6.01 billion in 2023, is projected to surge to
USD 43.04 billion by 2034, with an impressive CAGR of 20.7% from 2024 onward.

Meanwhile, the anti-viral nasal spray market is
gaining traction and is poised for significant revenue growth, with projections
indicating it may reach several hundred million dollars by 2034.

Viral Vector Development Market Top
Companies

• Lonza Group AG

• Merck KGaA

• Thermo Fisher
Scientific Inc.

• Catalent Inc.

• WuXi AppTec

• FUJIFILM Corporation

• Oxford Biomedica.

Recent Developments in the Viral Vector Development Market

➢ In July 2025, CD Bioparticles, a global
manufacturer and supplier of numerous drug delivery products and services,
introduced its expanded, one-stop AAV Vector Design services to help
researchers in progressing advancements in gene therapy and delivery, such as
the design, construction, and cloning of custom Adeno-Associated Virus (AAV)
vectors, as well as professional virus packaging services.

➢ In May 2025, Coave Therapeutics, a
biotechnology company, launched a CNS-targeted gene therapy capsid developed
with its proprietary platform.

➢ In May 2024, Charles River Laboratories
International, Inc., unveiled its reference materials for adeno-associated
virus (AAV) and lentiviral vector (LVV) portfolio, created to simplify Cell and
Gene Therapy (CGT) research and development as it scales to Good Manufacturing
Practice (GMP) quality.

Viral Vector Development Market
Segmentation

By Virus

•  Lentiviral Vectors

•  Adenoviral Vectors

•  Adeno-Associated
Viral Vectors- dominated

•  Retrovirus-
significant

By Expression System

•  Transient

•  Stable

By Application

•  Gene Therapy-
dominated

•  Vaccines

•  Cancer Therapy-
fastest

•  Others

By End User

•  Pharmaceutical
& Biotechnology Companies- dominated

•  Contract Research
Organization (CRO)- fastest

•  Academic and
Research Institutes

By Region

•  North America

•  Asia Pacific

•  Europe

•  Latin America

•  Middle East and
Africa (MEA)

Immediate Delivery Available | Buy
This Premium Research: https://www.towardshealthcare.com/price/5783

Access our exclusive, data-rich dashboard
dedicated to the healthcare market – built specifically for decision-makers,
strategists, and industry leaders. The dashboard features comprehensive
statistical data, segment-wise market breakdowns, regional performance shares,
detailed company profiles, annual updates, and much more. From market sizing to
competitive intelligence, this powerful tool is one-stop solution to your
gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical
research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we
build strategic partnerships that generate actionable insights and
transformative breakthroughs. As a global strategy consulting firm, we empower
life science leaders to gain a competitive edge, drive research excellence, and
accelerate sustainable growth.

You can place an order or ask any
questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

Web: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Â